Rheumatoid arthritis patients often don't notice disease flares until symptoms have already worsened substantially. As joint ...

Both upadacitinib (Rinvoq) and adalimumab (Humira) are proven effective in rheumatoid arthritis (RA) and psoriatic arthritis ...

SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost ...

A phase 3 rheumatoid arthritis trial of Lynk Pharmaceuticals’ JAK1 inhibitor in China has hit its primary endpoint, boosting ...

Nearly 1.5 million Americans and nearly 5% of women over the age of 55 have rheumatoid arthritis (RA), an incurable ...

Augurex CEO Neil Klompas describes why it is difficult for biomarkers to diagnose rheumatoid arthritis in some cases.

Discover effective strategies to manage arthritis pain during winter, including diet, exercise, and warmth for improved ...

Lynk’s zemprocitinib commercial partner, Simcere, will now continue the JAK inhibitor’s development across China in RA.

SetPoint Medical, a company dedicated to developing therapies for people living with chronic autoimmune diseases, today ...

Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as Lynk Pharmaceuticals), a clinical stage innovative drug ...

Patients with rheumatoid arthritis (RA) who receive immune checkpoint inhibitor (ICI) therapy for cancer do not appear to face higher mortality compared against patients without RA receiving the same ...